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EDITORIAL

Vascular Access: Inukshuk
n inukshuk (pl. inuksuit) is a ﬁgure constructed from
unworked stones or boulders (Fig 1) that is used for
communication among the Inuit in the Arctic.1 In Inuktitut, the language of the Inuit, inukshuk means “to act in
the capacity of a human.” Inuksuit serve several functions
including acting as hunting and navigational aids, coordination points, and messaging centers. In addition to their
practical functions, inuksuit are venerated and possess
spiritual connotations. For those who survive and thrive
in the Arctic in the “Old Way,” mindfulness and appreciation of the import of guidepost inuksuit are critical.
The need for guidepost inuksuit arises when considering
hemodialysis (HD) vascular access, one of the most vexing
problems of clinical nephrology. Vascular access failure
results in an untimely burden for many: dialysis workers,
healthcare providers, and, most importantly, patients. Failure of a vascular access portends multiple possibilities,
none of them good. There are missed HD treatments, surgical revision(s), and their associated pain(s) and cost(s).
There is blood loss, exposure to nephrotoxic contrast
medium with possible reduction in residual kidney function, and macerated and propellant clots associated with
pulmonary emboli during thrombectomy procedures. A
forced and failed arteriovenous ﬁstula (AVF) leads to
morbidity for the patient in disﬁguring scars and their
ostracizing effects, loss of future vascular access options,
and urgent requirement for alternative vascular access.
The latter is arguably the worst scenario and requires temporary placement of an HD catheter that potentially leads
to one of the 80,000 central line–associated bloodstream
infections (CLABSIs) that occur in the United States annually.2 These infections result in 28,000 intensive care unit
deaths yearly and, on average, cost $45,000 per episode.3
Even worse, some individuals will survive an episode of
life-threatening sepsis only to encounter another as the ﬁstula failure-to-dialysis catheter insertion cycle repeats itself.
The Centers for Medicaid and Medicare Services
(CMS)–sponsored Arteriovenous Fistula First Breakthrough Initiative (FFBI) was developed as the National
Vascular Access Improvement Initiative in 2003 and
launched nationally in 2004.4 This programmatic push
for increasing AVF prevalence followed the 1997
National Kidney Foundation Kidney Disease Outcomes
Quality Initiative recommendation for an incident
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autogenous AVF rate of 50%, with an ultimate 40% prevalence rate. The second, complementary guideline was a
10% prevalence of HD catheters.5 This FFBI prevalence
target of 40% was rapidly adopted as a quality metric
by healthcare groups, hospitals, and the 18 end-stage
renal disease (ESRD) networks in the United States. In
2009, the benchmark goal increased to 66% AVF use in
prevalent HD patients, which was considered feasible,
particularly because other countries boasted prevalences
from 67% to 91% in Japan, Italy, and Germany.6
This laudable initiative likely failed because it was
ﬂawed in several aspects. In previous editorials, I had discussed the “systematization of harm”7 and “misfears”.8,9
Both applied in this case. First, the FFBI evoked the
specter of measurement and self-recrimination. Groups
and institutions that embraced the initiative but scored
below target AVF rates were considered less capable
than others, which spurred an emotion-laden call to action
to create AVFs on demand and without an optimized and
individualized plan. Ironically, adoption of the FFBI led to
an 80% incidence of temporary HD catheter insertions,10
by inadvertently diverting attention from initiatives to
decrease catheter use.11 Thus, this sequence of events represented an inadvertent systematization of harm, and
Lacson and colleagues proposed a solution of bridge
grafts to subvert the dangers inherent to catheters. Elderly
candidates who should not have undergone surgery to
establish an AVF were moved to the front of the line for
this delicate procedure, in many instances to increase
the local AVF prevalence, but these individuals received
grave disappointment when the AVF did not mature, resulting in a lost vein, non-recoverable time, and prolongation of central venous catheterization. This costly scenario
was repeated ad inﬁnitum and chalked up to “bad luck”
and a search for improvement.
In elderly patients, there may be no clear-cut advantage
to AVF over arteriovenous graft (AVG) construction. Here,
the misfear—instinctive rather than factual—is that AVG
placement will fail and the patient will require a future,
Ó 2015 by the National Kidney Foundation, Inc. All rights reserved.
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in the same way that inuksuit situated throughout the
Arctic landscape act as “helpers” to the Inuit. Three of
these tools have been validated and may be easily implemented.

Figure 1. Inukshuk at the mouth of the Great Whale River in
the vicinity of Kuujjuarapik, the southernmost village of
Nunavik. Photograph, courtesy of Nicolas M. Perrault.

secondary procedure. Consequently, an AVF is attempted
although great doubt exists regarding the suitability of the
AVF postsurgically. Not infrequently, a secondary procedure is required to facilitate its use. The data from the
Dialysis Access Consortium trials demonstrated a high
rate (60%) of suitability failure for autogenous AVFs
when deﬁning suitability as “use of the AVF at a dialysis
machine blood pump rate of 300 mL/min or more during 8
of 12 dialysis sessions.”12 Considered by many a benchmark trial, the outcome was not because vascular access
surgeons have always understood that careful patient selection is fundamental to access. In a parallel trial, Dixon
and colleagues demonstrated the difﬁculty inherent to
successful graft constructions.13 Graft failure occurred in
nearly three-fourths of subjects after 1 year of observation,
and the addition of long-acting pyridamole and aspirin
did not offer a conclusive advantage over that of placebo
for prophylaxis against thrombosis prevention.
If an individual, usually elderly with suboptimal caliber
and quality veins, is subjected to “failure to mature”
(FTM) testing and will predictively fail AVF maturation
and use, an AVG is the ﬁrst choice or the alternative of
peritoneal dialysis. Perversely, failure of AVF construction
enriches those who perform them. Driven by pressure to
achieve an AVF prevalence metric, ﬁrst 50% then 66%,
AVF constructions that were likely to fail did so, leading
to secondary synthetic AVG constructions after intervening catheter insertions—all executed and billed by
the same individual. Finally, even the best AVFs may
bear unforeseen consequences including aneurysmal dilation with erosion, left ventricular hypertrophy, high
output cardiac failure, or a vascular “steal” syndrome.
Could we reduce these potentially lethal events by
following our own inuksuit? Such a rhetorical question
begs no answer, and there are and have been inuksuit
that exist and facilitate the goal of optimal vascular access
for each individual who requires one. These tools assist
nephrologists to navigate the vascular access landscape

FAILURE TO MATURE INDEX
Lok and colleagues offer a solution to determining a priori the best vascular access for each patient in a timely
fashion. Certainly, AVFs may sustain greater blood
ﬂow than AVGs, but that is not the only qualifying criterion for success. A simple, rigorously validated scoring
system, developed by Lok and colleagues, predicts a
preoperative AVF FTM rate using clinical parameters.14
FTM is a function of age, coronary artery disease, peripheral vascular disease, and race. In terms of peripheral vascular disease, it is known that neointimal
hyperplasia may be surreptitiously present before
vascular access investigations are even contemplated.15
The FTM prediction equation (score ¼ 3 1 2 3 [years
$ 65] 1 3 3 [PAD, peripheral arterial
disease] 1 2.5 3 [CAD, coronary artery disease] 2
3 3 [white]) was externally validated in 461 patients
from 4 Canadian and 1 US dialysis centers and scored
from 0 to 10.5 along the following 4 risk categories:
,2.0, low risk; 2.0 to 3.0, moderate risk; 3.1 to 7.9, high
risk; and $8.0, very high risk. The primary outcome
was AVF FTM, operationally deﬁned as an AVF that
was unable to consistently provide prescribed dialysis
via 2-needle cannulation for 1 month within 6 months
of its creation. Interventions that promoted AVF maturation were permitted at the discretion of the treating provider(s), including nephrologists, interventionalists, and
vascular surgeons. As anticipated, older black individuals had greater FTM risks, which was ampliﬁed by
the presence of cardiovascular disease. Half of patients
graded at high risk experienced FTM, and 69% of individuals with very high risk for FTM experienced AVF
failure. The ﬁnancial savings of calculating the risk prediction score in very high–risk individuals are substantial, notwithstanding the beneﬁts to the patients who
can avert an unfavorable surgical outcome(s). Because
surgical opinion plays a signiﬁcant role preoperatively,
education regarding the appropriateness of AVF construction surgery represents an opportunity for meaningful collaboration, fortiﬁed by a robust vascular
access database.
VASCULAR ACCESS SURVEILLANCE
Physical examination is the prototypical vascular access
“monitoring” modus operandus, but it is a dying art.
Physical examination of vascular access has been
extended to include clinical clues such as symptoms and
recirculation.16 Rapid throughput medicine and the lack
of hands-on teaching, attributable to a paucity of skilled
examiners trained in this fundamental skill, have instigated this sorry state of affairs. Compounding this suboptimal situation, vascular access evaluation has physical
and operator-dependent limitations. Certain key physical
ﬁndings are contextually dependent on blood ﬂow, a dynamic characteristic that may be inconstant, for example,
in atrial ﬁbrillation. In addition, physical ﬁndings
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predictive of vascular access dysfunction may require
achievement of thresholds of obstruction before detection.
By contrast, vascular access “surveillance,” functionally
continuous access monitoring, requires specialized tests
and instruments, which are employed periodically.
Accordingly, additional detection methods for vascular
access dysfunction have been explored. This conduit
complication when slowly progressive may be signaled
by escalation of blood urea nitrogen and veriﬁed by the
classical, tripartite, blood urea nitrogen recirculation
study. Because of this procedure’s exacting and timeintensive nature, this technique is rarely performed on a
routine basis today by any in-center HD units. Fortunately, the proxies of conductivity testing and observation
of sodium dialysance monitoring have supplanted the
classical recirculation study. Elevated intra-access pressure (IAP) has been studied as a warning sign for vascular
access dysfunction and impending thrombosis. Static IAP
of AVFs and AVGs as an original surveillance mechanism
was developed by Besarab and colleagues more than 2 decades ago.17 This parameter normalized by the systolic
blood pressure correlated with access recirculation, AVF
and AVG thrombosis, reduced blood ﬂow, requirement
for surgical intervention, and access failure. Its positive
predictive value was sufﬁciently high to promote its
adoptability, but the scrupulous technique required for
widespread deployment limited adoptability.
Similarly, periodic, duplex ultrasonographic probing of
vascular accesses and the ultrasound dilution technique
proved successful in the early detection of vascular access
thrombosis in a study by May and colleagues.18 Ultrasonography has 2 intrinsic costs: purchase of a relatively
costly device and personnel. The latter cost stems from
the time and dedicated manpower that is intrinsic to establishing technique precision and reproducibility. Typically, a single individual in an HD unit was entrusted
with the responsibility of ultrasonic detection of vascular
access dysfunction, and this became a full-time job.
Due to time constraints, most patients could not even
undergo surveillance weekly or monthly, greatly dissipating the capability of the instrument to detect access
dysfunction. For now, cost considerations and dedication
to the craft of ultrasonography preclude its widespread
applicability. Ram and colleagues could not demonstrate
superiority of ultrasonographic surveillance compared
with aggressive clinical monitoring in a randomized,
controlled trial.19
Amplifying the strengths of IAP observation, surveillance of vascular accesses is feasible. The IAP can be
rapidly and proxy calculated using accessible, hemodialysis machine-based data collected automatically and
frequently.20 A computerized algorithm (Vasc-Alert)
dynamically determines venous intra-access pressure
from the venous drip chamber pressure during hemodialysis machine operation. This parameter is derived from
the venous drip chamber pressure, blood pump ﬂow
data, and a recent hematocrit (viscosity index). Periodic
extraction of individual treatment data is fed forward to
a remote database. Similar to the systolic pressurenormalized IAP, a venous access pressure ratio (VAPR)
is deﬁned as the ratio of the venous intra-access pressure
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(VAP) to the mean arterial pressure (MAP). This ratio is
termed the vascular access pressure ratio (VAPR). VAPRs
are iteratively calculated whenever timed blood pressure
measurements are carried out and averaged per dialytic
session. Data within the ﬁnal 60 minutes of a dialysis
treatment are excluded to eliminate the effect of ultraﬁltration on hematocrit, blood pressure, and consequential alterations of resistances in the systemic and vascular access
circuits. Abnormal mean VAPRs are those that surpass a
prespeciﬁed upper bound in trended fashion, namely during 3 consecutive treatments.
Elevated VAPRs correlate with vascular access dysfunction in AVGs, and similar correlations are anticipated in
AVFs. Anomalous AVG ﬂow is also detectable by dynamic access pressure surveillance. Importantly, hemodialysis is never interrupted by this technique, and large
amounts of patient-level and unit-level data are autoreported to in-center dialysis unit healthcare providers
for rapid interpretation. When high venous access pressure ratio warnings are transmitted, the healthcare provider is alerted to the presence of vascular access
dysfunction and access evaluation by a vascular access
surgeon can be facilitated. Zasuwa and colleagues delineated the effectiveness of automated intravascular surveillance.21 Using a computerized algorithmic approach,
thrombosis rates declined progressively in AVGs and
AVFs, with the magnitude of effect greater in AVGs than
autogenous AVFs.
ANTIMICROBIAL/ANTIBIOTIC HD CATHETER LOCKS
When all else fails, a hemodialysis catheter becomes
necessary unless the patient opts for peritoneal dialysis—an excellent upfront choice. Excellent catheter care
in a given hemodialysis unit does not translate to 24/7 vigilance, and catheter infection rates escalate slowly for
90 days before achieving a steep upward trajectory. The
source of a catheter infection—itself a misnomer—is
bioﬁlm that progressively forms on the catheter. This
microorganism-manufactured matrix dually confers antibiotic resistance while providing a nutrient environment
for its residents, which alternate between a sessile,
slime-making existence in a condominium constructed
of an extracellular polymeric substance and a ﬂagellar,
planktonic lifestyle in the bloodstream. Catheters impregnated with substances such as silver22 are designed to
prevent microorganism colonization or disrupt bioﬁlm
formation have also been combined with anti-infectives
such as chlorhexidine in successful clinical trials that did
not include hemodialysis patients.23 However, hemodialysis catheters that are instilled with high concentrations of
antimicrobials at the end of a dialysis session—antimicrobial locks—have proven the most effective strategy in
the reduction of CLABSIs. This particular strategy is
3 decades old.24
To date, the great majority of trials that investigated the
safety and utility of antimicrobial locks have been positive. Various antimicrobial locks have been successfully
investigated in clinical trials including minocycline,25
taurolidine,26 gentamicin/citrate solutions,27 a mixture of
citrate/methylene blue/parabens.28 Ethanol at a concentration of 70% has also been studied, but published data do
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not yet support routine utilization of ethanol antimicrobial locking.29 In the Heparin vs EthAnol Lock THerapY
for the prevention of Catheter Associated infecTion in
Haemodialysis trial, a deﬁnitive conclusion could not be
drawn as the study was underpowered by under-recruitment. Heparin was used in some trials with the thought
that high, local concentrations might preclude or forestall
bioﬁlm formation. This strategy was ineffective in vitro
with citrate/methylene blue/parabens, and Hemmelgarn
and colleagues in the PreClot study posited that heparin
nurtured the development of bioﬁlm.30 Later, Moore
and colleagues delineated a reduction of CLABSI of 73%
in a single-center study of 555 participants and 1350 catheters using an antimicrobial lock of gentamicin/citrate solution vs a heparin-control group (0.45 per 1000 catheter
days vs 1.68 per 1000 catheter days; P ¼ 0.001).31 Furthermore, a mortality beneﬁt of gentamicin/citrate was revealed (hazard ratio, 0.32), whereas no increase of
antibiotic resistance was found (antibiotic lock group,
0.22 per 1000 person years vs heparin-control, 0.45). In a
study antedating that of Moore’s, Landry and colleagues
disclosed the emergence of gentamicin resistance in their
investigation of a gentamicin-heparin lock,32 prompting
discontinuation of heparin after 6 months. Overall, citrate
substitution for heparin, or the omission of heparin, appears fundamental to the avoidance of antibiotic resistance.
Despite the positive outcomes of clinical trials of antimicrobial locks, this easy-to-learn, adoptable, and implementable technique has few devotees despite an
unambiguous admonition by Landry and Braden to practicing nephrologists that the important decision is not if
but when to implement an antibiotic lock strategy.33 Fears
of the development of antibiotic resistance from implementation of a “lock” were not irrational, but negating
the evidence that resistance clearly has not been the natural consequence of their use and ignoring their positive
beneﬁts during a dire clinical circumstance is illogical.
This is a type 2 clinical error. Principally, the concept
that an antibiotic lock must engender microbial resistance
is a non sequitur.
The conﬂation of the necessary physical and biological
characterization of AVFs will hopefully optimize vascular
access modality choice and increase the AVF rate in those
who will beneﬁt from AVF construction. Only in this way
will the true prevalence of mature AVFs be established.
Greater predictive accuracy than the FTM risk score provides may eventuate from a computational approach,
with robust decision matrices that interrogate for all that
can be known about a patient’s vascular access preoperatively, and facilitate pragmatic AVF outcomes. Currently,
2 predictive models that use ultrasonographic ﬁndings
and non-gadolinium contrast-enhanced magnetic resonance angiography provide anticipated vascular access
blood ﬂow rates before vascular access surgery is attempted.34,35 Such predictive models offer the way forward in
conjunction with excellent clinical judgment that considers
the individual clinical and functional characteristics, life
circumstances, and preferences of patients.
I cannot fathom an Arctic aboriginal ignoring an inukshuk assembled by another experienced traveler-pioneer

communicating a warning or sage advice from centuries
ago. In terms of vascular access, we have our own pioneers with their inuksuit and should heed those who built
them to act in the capacity of a physician with the best interests of patients at heart. The FFBI essentially sets a “one
size ﬁts all” standard, always a ﬂawed approach. Nonetheless, the AVF rate remains within the scope of work
of the ESRD networks. This harangue is promulgated by
the implementation of the 2014 CMS “Five Star” rating
system, which was added to the CMS Dialysis Facility
Compare Web site.36 All told, FFBI has made us aim
higher, and our contemporary inukshuk, the FTM risk
scoring system, dynamic vascular access surveillance,
and antimicrobial locks, will improve functioning
vascular access rates and optimize the desired “Patient
First” approach as espoused by Lok and colleagues. The
traditional meaning of “inukshuk” is “you are on the right
path,” and now we are.
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